Combined administration of rifampicin and glucocorticoids;A propos de l'association rifampicine - glucocorticoides

Revue de Medecine Interne

Volumn 19, Issue 5, 1998, Pages 303-304

  Levesque, H ^a   Lecomte, F ^a  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

Author keywords

Drug interactions; Pharmacokinetic; Prednisolone; Rifampicin

Indexed keywords

GLUCOCORTICOID; RIFAMPICIN;

ANTIBIOTIC THERAPY; COMBINATION CHEMOTHERAPY; EDITORIAL; HUMAN; STEROID THERAPY; TUBERCULOSIS;

EID: 0031840999     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(98)80098-2     Document Type: Editorial

References (14)

1. American Thoracic Society Treatment of tuberculosis and tuberculosis infection in adults and children Am J Respir Crit Care Med 149 1994 355 363
2. Wehrly W Rifampicin: mecanisms of action and resistance Rev Infect Dis 5 suppl 3 1989 407 411
3. Swoebel V Épidémiologie de la tuberculose: du nouveau ? Rev Méd Interne 16 suppl 1 1995 29 32
4. Steele M Burk R Desprez R Toxic hepatitis with isoniazid and rifampicine: a meta-analysis Chest 99 1991 465 471
5. Zilly W Breimer DD Richter E Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance Eur J Clin Pharmacol 9 1977 219 227
6. Sepkowitz KA Raffalli J Riley L Kiehn TE Armstrong D Tuberculosis in the AIDS Era Clin Microbiol Rev 8 1995 180 199
7. Barry M Gibbons S Back D Mulcahy F Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetics considerations Clin Pharmacokinet 32 1997 194 209
8. Carrie F Roblot P Bouquet S Delon A Roblot F Becq-Giraudon B Rifampicin-induced nonresponsiveness of giant cell arteritis to prednisone treatment Arch Intern Med 154 1994 1521 1549
9. Darras-Joly C Wechsler B Blétry O Le Thi Huong Du Raguin G Godeau P Tuberculose maladie et maladies systémiques. À propos de 16 cas Rev Méd Interne 19 1998 91 97
10. Mc Alisier W Thompson PJ Al Habet SM Rogers HJ Rifampicin reduces effectiveness and bioavailability of prednisolone Br Med J 286 1983 923 925
11. Lee KH Shin JG Chong WS Kim S Lee JS Jang IJ Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampicin Eur J Clin Pharmacol 45 1993 287 289
12. Grosset J Leventis S Adverse effects of rifampicin Rev Infect Dis 5 suppl 3 1983 440 446
13. Calleja C Pascussi JM Mani JC Maurel P Vilarem MJ The antibiotic rifampicin is a non steroidal ligand and activator of the human glucocorticoid receptor Nature Med 4 1998 92 96
14. Blanchard JS The ying and yang of rifampicin Nature Med 4 1998 14 15